This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keezer, S. M. Articles by Roberts, D. D. Search for Related Content PubMed PubMed Citation Articles by Keezer, S. M. Articles by Roberts, D. D.

Angiogenesis Inhibitors Target the Endothelial Cell Cytoskeleton through Altered Regulation of Heat Shock Protein 27 and Cofilin¹

Laboratory of Pathology [S. M. K., S. E. I., H. C. K., D. D. R.] and Surgery Branch [A. T., S. K. L.], National Cancer Institute, NIH, Bethesda, Maryland 20892

Inhibition of angiogenesis has emerged as a key focus for the treatment of cancer, necessitating a better understanding of the downstream molecular targets of angiogenesis inhibitors. Endostatin, thrombospondin-1, fumagillin, and its synthetic derivative, TNP-470, are potent inhibitors of endothelial cell proliferation and migration in culture and of angiogenesis in vivo. To identify targets that mediate the effects of these inhibitors, we compared two-dimensional gel electrophoresis patterns from lysates of treated and untreated human endothelial cells. Among the proteins identified were cofilin and hsp27, two proteins involved in actin dynamics. Western blotting and immunofluorescence experiments confirmed that the phosphorylation states and subcellular localization of these two proteins were affected by all of the inhibitors tested and that treated cells had a more extensive network of actin stress fibers and more numerous focal adhesion plaques compared with untreated cells. Endothelial monocyte activating polypeptide II, another angiogenesis inhibitor, elicited the same response in the actin cytoskeleton and focal adhesions of endothelial cells. This more adherent phenotype may explain the shared ability of these inhibitors to block endothelial migratory signals. Starting with a proteomics approach, we have identified common effector molecules used by a panel of angiogenesis inhibitors that perturb the cytoskeleton to prevent endothelial migration.

This article has been cited by other articles:

				M. Kwon, E. Hanna, D. Lorang, M. He, J. S. Quick, A. Adem, C. Stevenson, J.-Y. Chung, S. M. Hewitt, E. Zudaire, et al. Functional Characterization of Filamin A Interacting Protein 1-Like, a Novel Candidate for Antivascular Cancer Therapy Cancer Res., September 15, 2008; 68(18): 7332 - 7341. [Abstract] [Full Text] [PDF]

				A. Dimberg, S. Rylova, L. C. Dieterich, A.-K. Olsson, P. Schiller, C. Wikner, S. Bohman, J. Botling, A. Lukinius, E. F. Wawrousek, et al. {alpha}B-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis Blood, February 15, 2008; 111(4): 2015 - 2023. [Abstract] [Full Text] [PDF]

				Y.-G. Tong, X.-W. Zhang, M.-Y. Geng, J.-M. Yue, X.-L. Xin, F. Tian, X. Shen, L.-J. Tong, M.-H. Li, C. Zhang, et al. Pseudolarix Acid B, a New Tubulin-Binding Agent, Inhibits Angiogenesis by Interacting with a Novel Binding Site on Tubulin Mol. Pharmacol., April 1, 2006; 69(4): 1226 - 1233. [Abstract] [Full Text] [PDF]

				W. Zuidervaart, P. J. Hensbergen, M.-C. Wong, A. M. Deelder, C. P. Tensen, M. J. Jager, and N. A. Gruis Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 786 - 793. [Abstract] [Full Text] [PDF]

				S. Bohman, T. Matsumoto, K. Suh, A. Dimberg, L. Jakobsson, S. Yuspa, and L. Claesson-Welsh Proteomic Analysis of Vascular Endothelial Growth Factor-induced Endothelial Cell Differentiation Reveals a Role for Chloride Intracellular Channel 4 (CLIC4) in Tubular Morphogenesis J. Biol. Chem., December 23, 2005; 280(51): 42397 - 42404. [Abstract] [Full Text] [PDF]

				L. M. McHardy, K. Warabi, R. J. Andersen, C. D. Roskelley, and M. Roberge Strongylophorine-26, a Rho-dependent inhibitor of tumor cell invasion that reduces actin stress fibers and induces nonpolarized lamellipodial extensions Mol. Cancer Ther., May 1, 2005; 4(5): 772 - 778. [Abstract] [Full Text] [PDF]

				G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311. [Abstract] [Full Text] [PDF]

				D. K. Skovseth, M. J. T. Veuger, D. R. Sorensen, P. M. De Angelis, and G. Haraldsen Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo Blood, February 1, 2005; 105(3): 1044 - 1051. [Abstract] [Full Text] [PDF]

				C. M. Mazzanti, A. Tandle, D. Lorang, N. Costouros, D. Roberts, G. Bevilacqua, and S. K. Libutti Early Genetic Mechanisms Underlying the Inhibitory Effects of Endostatin and Fumagillin on Human Endothelial Cells Genome Res., August 1, 2004; 14(8): 1585 - 1593. [Abstract] [Full Text] [PDF]